Kong et al listed criteria for metabolic response following therapy to a a non-small-cell lung cancer as seen on a positron emission tomography (PET) scan. The authors are from the University of Michigan and Veterans Affairs Health Center in Ann Arbor.
Patient selection: non-small-cell lung cancer (NSCLC)
Imaging study: PET scan using [18F] fluorodeoxyglucose (FDG)
Timing: at least 6 to 8 weeks after radiation therapy and 2 weeks after chemotherapy (to minimize FDG uptake in inflammation triggered by the therapy).
Measurements:
(1) pretreatment FDG uptake in the tumor in standard uptake units (SUV)
(2) FDG uptake in the tumor at follow-uo
(3) mean SUV uptake of the aortic arch
percent FDG uptake at followup compared to pretreatment uptake =
= (SUV at followup) / (SUV at pretreatment) * 100%
FDG Uptake at Followup |
Ratio of FDG at Follow-Up to Pretreatment |
Metabolic Status |
< mean uptake of the aortic arch |
NA |
complete metabolic response (CMR) |
>= mean uptake of the aortic arch |
<= 70% |
partial metabolic response (PMR) |
>= mean uptake of the aortic arch |
71 to 119% |
stable metabolic disease (SMD) |
>= mean uptake of the aortic arch |
>= 120% |
progressive metabolic disease (PMD) |
Purpose: To determine the metabolic response to therapy seen in a non-small-cell lung cancer (NSCLC) on [18F]FDG PET scan.
Specialty: Hematology Oncology, Surgery, general
Objective: response to therapy
ICD-10: C39.9,